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Abstract 
Background 
Sub-optimal adherence to inhaled steroids is common in children with asthma and is 
associated with poor disease control, reduced quality of life and even death. Previous 
studies using feedback of electronically monitored adherence data have demonstrated 
improved adherence but have not demonstrated a significant impact on clinical outcomes. 
The aim of this study was to determine whether introduction of this approach into routine 
practice would result in improved clinical outcomes.  
Methods 
Children with  asthma aged 6-16 years were randomised to the active intervention 
consisting of electronic adherence monitoring with daily reminder alarms together with 
feedback in the clinic regarding their inhaled corticosteroid use or to the usual care arm 
with adherence monitoring alone. All children had poorly controlled asthma at baseline, 
taking inhaled corticosteroids (ICS) and long acting beta agonists (LABAs).   Subjects were 
seen in routine clinics every three months for one year. The primary outcome was the 
Asthma Control Questionnaire (ACQ) score. Secondary outcomes included adherence and 
markers of asthma morbidity. 
Results 
77 of 90 children completed the study (39 intervention, 38 control).  Adherence in the 
intervention group was 70%, vs 49% in the control group (p = <0.001). There was no 
significant difference in the change in ACQ but children in the intervention group required 
significantly fewer courses of oral steroids (p= 0.008) and fewer hospital admissions (p= 
<0.001).  
Conclusion  
The results indicate that electronic adherence monitoring with feedback is likely to be of 
significant benefit in the routine management of poorly controlled asthmatic subjects.   
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What is the key question? 
Can electronic adherence monitoring with feedback and alarms improve clinical outcomes in 
children with poorly controlled asthma? 
What is the bottom line? 
Electronic monitoring with feedback and alarms improved adherence, decreased hospital admissions 
and courses of oral steroids required.  
Why read on? 
This study provides the first unequivocal evidence that adherence monitoring with feedback can 
impact on important clinical outcomes when used in the management of children with poorly 
controlled asthma. 
 
Twitter 
Electronic adherence monitoring with feedback and alarms can be effectively used in the clinical 
setting to improve clinical outcomes for children with asthma. 
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INTRODUCTION 
Adherence to inhaled steroids is often sub-optimal in children with asthma, resulting in    poor 
disease  control1, increased need for oral steroids2 and decreased lung function3. This leads to 
increased healthcare utilisation, and associated cost4. The recent National Review of Asthma Deaths 
in the UK  reported that poor adherence was associated with 34% of deaths due to asthma, 
emphasising the significance of the problem5. 
Large adult population studies, and smaller paediatric studies have shown that adherence rates of 
75-80% are required to significantly improve asthma control6-8. However, when objectively 
measured, the average rate of adherence in children with asthma is around 50%, some way below 
this desired therapeutic level9. 
Subjective and indirect measurements of adherence have been shown to over-estimate rates due to 
patients wanting to be looked upon favourably by their clinician- the social desirability bias10,11. 
Electronic monitoring devices (EMDs) record adherence rates by logging the exact date and time an 
inhaler is actuated, with modern devices proven to be highly accurate and reliable in the clinical 
setting12. Monitoring allows intentional adherence barriers such as negative illness perceptions or 
medication beliefs to be identified, and addressed with regular open dialogue13-15. Reminder alarms 
built into the devices can address non-intentional practical barriers such as simply forgetting to take 
the medication16.  
Due to their cost, the British Thoracic Society (BTS) has questioned the viability of EMDs outside the 
research setting17,  and The National Insitute of Heath and Excellence (NICE) has recomended further 
studies to investigate their use clinically. 18.  . 
An Australian study demonstrated that children’s adherence increased when electronic data was fed 
back, although it was under-powered to show any improvement in clinical outcomes19.   A recent 
study in New Zealand improved self-reported asthma control in the short-term using electronic 
monitoring, no feedback and reminder alarms20. However, this study involved seeing subjects out of 
clinic every 2 months, used covert monitoring, and had no effect on objective clinical outcomes.   
In order to determine whether clinically relevant benefits could be observed in a routine clinical 
setting through the use of electronic monitoring we undertook a study in which children with poorly 
controlled asthma were randomised to the use of reminder alarms and feedback or routine care.  
5 
 
We hypothesized that by addressing both the intentional and non-intentional adherence barriers, 
rates would increase to a degree necessary to improve asthma control and clinical outcomes.  
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METHODS 
The STAAR study (STudy of Asthma Adherence Reminders) was a multi-centre, open label, parallel 
group randomised controlled trial, with an allocation ratio of 1:1.  Written consent was taken from 
the parents/ carers of all participants, and ethical approval for the study was granted by the South 
Yorkshire Research Ethics committee , REC reference 13/YH/0289. The protocol was registered with 
ClinicalTrials.gov, number NCT02451709.  
Participants & setting 
Children with doctor-diagnosed asthma aged 6-16 years attending   clinics in Sheffield or Rotherham 
were screened for eligibility. Participants had to be taking regular inhaled steroids, with no change in 
their medication in the last month. At recruitment, participants had to have an Asthma Control 
Questionnaire (ACQ) score of at least 1.5, indicating they had poorly controlled asthma21. 
Participants were excluded if they  couldn’t speak English, or if they had another significant chronic 
condition.  The EMDs  available for this trial were only compatible with seretide or symbicort 
inhalers. Therefore all participants were at BTS level 3 at the start of the trial. 
Interventions  
Prior to randomisation, all participants had their inhaler technique checked by a qualified asthma 
nurse, andreceived a brief asthma education session, teaching the basic aetiology of asthma, and the 
importance of regular inhaled steroids as treatment. All participants were seen in their standard 
asthma clinics at 3 monthly intervals and all treatment decisions were made by the clinical team.   A 
member of the study team downloaded data from the EMD  at each visit.   
Intervention Group 
Participants in the intervention group had an EMD  attached to their regular inhaler. The devices 
used in this study were “smartinhalers” and “smartturbos”, manufactured by Adherium, [Auckland, 
New Zealand] (figure 1).   The EMDs are commercially available, have a CE safety mark, and are 
validated for adherence monitoring in asthma12. Participants were told the devices monitored how 
much the inhaler was taken, and the date and time of all actuations. At clinic visits, the adherence 
data from the previous 3 months was uploaded to the website www.smartinhalerlive.com. These 
data were reviewed as a graph with the patient and parent/ carer, and a member of the study team 
(figure 2). This graph shows the amount and times inhalers were taken each day.  Open, non-
judgemental discussions were held about the adherence rate,  barriers identified, and if necessary, 
7 
 
personalised strategies for improvement were devised. An agreed adherence target was set for the 
next clinic by the patient, study team, and parent/ carer.    
The participants’ devices were set  to play reminder alarms at agreed times, with different times for 
weekdays and weekends. The alarms were popular children’s music,  or character noises. Alarms 
would only sound if the inhaler had not been actuated within the previous 6 hours of the specified 
time. Alarms sounded for 5 seconds, every minute for 15 minutes, or until the inhaler was actuated. 
The devices were locked to prevent tampering.. Times were reviewed each study visit and changed if 
necessary. An example was a child who missed  evening doses due to Arabic classes. This was 
identified and alarms set for later in the evening on weekdays.  
Control Group  
Control participants had the same EMDs attached to their regular inhaler,  they were also told the 
devices monitored how much the inhalers were taken, but that these data would not be reviewed. 
Participants were seen in their standard asthma clinic and the data was downloaded, but not 
reviewed. The alarms were disabled, and the devices locked. 
Primary Outcome 
The primary outcome for the study was change in the ACQ  score at 3, 6, 9 and 12 months. The ACQ 
is a questionnaire validated for the use in children aged 6-1622. There are 6 clinical questions related 
to  symptoms in the previous week, and the 7th score corresponds to the Forced Expiratory Volume 
in one second, per cent predicted (FEV1%). A mean of the 7 values is calculated, giving a score of 0-6, 
with a higher score indicating more poorly controlled asthma. 
Secondary Outcomes 
Secondary outcomes recorded  at baseline and each  visit were FEV1% 23, number of unplanned 
attendances to GP/ED for asthma since last visit (as reported by parents), number of r courses of oral 
steroids required, number of days off school due to asthma,  use of beta agonists in the past week 
(question score on the ACQ) and BTS level of asthma therapy. Quality of life was measured using the  
Mini Paediatric Asthma Quality of Life Questionnaire (mini PAQLQ)24.  The adherence rate was 
calculated for each 3 month period, both morning and afternoon doses, and recorded as a 
percentage. This was calculated as number of doses actually taken/ number of doses prescribed x 
100. The daily adherence was capped at 100%, to avoid falsely increased values due to dose 
dumping. The overall 3 monthly figure was a mean of each daily %. Parental beliefs about inhaled 
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steroids and perceptions about asthma were recorded at baseline and 12 months with the Beliefs 
about medicines questionnaire (BMQ) and the Brief Illness Perceptions Questionnaire (IPQ)25, 26. 
Sample Size 
The sample size was calculated using a repeated measures analysis for 4 follow-up visits. The 
Minimal Clinically Important Difference (MID) for the ACQ is 0.522. Using a repeat measure analysis 
table we calculated for a significance of 5% (α = 0.05), and a power of 80%, with a repeated measure 
correlation of 0.4, that n = 76 27. To allow for a 15% attrition rate we aimed to recruit 90 participants 
to the study. 
Randomisation 
Participants were randomised using  permuted block randomisation, with an allocation of 1:1, which 
resulted in equal group sizes of 45, created from a computer generated random number sequence. 
The allocation of subjects following recruitment involved phoning the independent holder of the 
randomisation code.   
Blinding 
Due to the nature of the intervention, neither the participants nor the study team were blinded in 
this study. In the intervention group adherence data was made available to clinicians if requested, 
but not in the control group. 
Statistical analysis 
The ACQ and FEV1% were compared statistically by two approaches.  First, by calculating a paired 
difference between 12-months and baseline for each group separately.  The ‘difference of the 
difference’ between treatments was compared by an independent t-test.  A 95% confidence interval 
was calculated.   Second, an area under the curve (AUC) was calculated for each group and the 
between-group difference was determined by an independent t-test.  The AUC is a mean value 
weighted by time 28.  An arbitrary level of 5% statistical difference was assumed (two-tailed).     
Incident rates were estimated by Poisson regression, and compared by incident rate ratios 
(IRRs)  The assumption of Poisson regression (mean=variance) was confirmed.  Continuously 
distributed data was summarised by the median (quartiles); categorical data by n (%). A sensitivity 
analysis was carried out on the primary outcome measure (ACQ) using multiple imputation 
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(MI). The approach used is explained in detail in appendix 1, with charts demonstrating the 
patterns for missing data. The “Stata” statistical computer package was used for data analysis.. 
 
RESULTS 
90  children  (81 Sheffield, 9 Rotherham) were recruited between October 2013 and August 2014, 
figure 3 shows the flow of these participants.    
Baseline characteristics 
The baseline characteristics are shown in table 1. 
 
 
 
 
 
 
 
 
 Intervention 
group (n=47) 
Control group (n=42) 
Age [years] 10.4 
(2.9) 
10.2 
(2.9) 
Sex male 28(60%) 22(52%) 
ACQ 2.5(0.8) 2.3(0.7) 
FEV1 % 87.2 (14.9) 88.0 (13.4) 
PQL 4.3(1.5) 4.6(1.2) 
ICS dose 697.9(348.6) 664.3(280.1) 
BTS 3.5(0.6) 3.4(0.5) 
Proportion BTS ≥ 
4 
51% 43% 
GP/ED visits 1.9(2.2) 2.1(2.0) 
Beta agonist 2.5(1.3) 2.3(1.3) 
School days 
missed 
3.5(4.4) 3.8(5.7) 
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Oral steroids 1.2(1.8) 1.2(1.3) 
Hospital 
admissions 
0.3(0.6) 0.2(0.6) 
BMQ score 2.5 (0.5) 2.6 (0.4) 
IPQ score 5.6 (1.3) 5.3 (0.9) 
Ethnicity WB 
                 BA 
                 BP 
                 BI 
                 AO 
                 BC 
30(64%) 
3(6%) 
11(23%) 
0(0%) 
1(2%) 
2(4%) 
24(57%) 
6(14%) 
11(26%) 
1(2%) 
0(%) 
0(%) 
Time from 
asthma 
diagnosis (years) 
6.0 (3.7) 6.7 (3.7) 
Table 1 – Baseline data. Data are mean (SD)or n (%).  Notes.  Calculations subject to rounding 
errors.  ACQ=asthma control questionnaire. FEV1% = Forced expiratory volume in 1 second, % 
predicted. PQL=paediatric quality of life questionnaire. ICS dose = beclometasone equivalent. Beta 
agonist use – score on ACQ question. WB=white British, BA=black African, BP=British Pakistani, 
BI=British Indian, AO=Asian other, BC=black Caribbean. GP/ED visits, school days missed, oral 
steroids required and hospital admissions are all parent reported events over the previous 3 
months. 
Primary Outcome 
The  ACQ  decreased in both groups between the baseline and the 3-month visit.  It fell by 1.0 in the 
control group and 0.9 in the intervention group (p=0.35), both significantly exceeding the  MID for 
changes in ACQ scores of 0.522.  This improvement was maintained to 12 months in both treatments 
arms (figure 4). At 12 months there were no significant differences between the two groups for 
either the mean change from baseline (table2) or the areas under the curve (table 3).  The individual 
participant trajectories for ACQ across the study visits are shown in appendix 1 (figure A3). 
Outcome Intervention 
baseline 
Intervention 
12 months 
Paired 
mean 
difference 
Control 
baseline 
Control 
12 
months 
Paired 
mean 
difference 
Difference 
of the 
difference 
95% CI p 
ACQ 2.65 
(0.12) 
1.58 
(0.19) 
-1.14 
(0.21) 
2.47 
(0.12) 
1.50 
(1.07) 
-0.95 
(0.77) 
-0.18 (0.28) 
 
-0.76,0.38 0.51 
 
FEV1% 87.23  (2.77) 91.37 (1.33) 3.00 (1.67) 88.00 
(1.07) 
88.97 
(2.55) 
1.54 (2.18) 1.45 (3.68) 
 
-4.00,6.91 0.59 
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Table 2.  Primary outcome measures.  Data are means (SD in parentheses).  The difference of the 
difference is an estimative statistic where the SD has limited value.
Intervention Control Difference 95% CI P 
1.7 (0.13) 1.6 (0.14) 0.09 (0.18) (-0.26,0.45) 0.52 
Table 3 – Comparison of areas under the curve for ACQ 
Secondary Outcomes 
Average adherence over the 12 months for the intervention group was 70%, vs. 49% for the control 
group (p=<0.001). Higher mean and median adherence rates were maintained for the 12 month 
period in the intervention group, but declined over time in the control group (figure 5). 20 
Participants in the intervention group, and 6 in the control group had a mean adherence rate of 
>80% for the 12 month period. 4 participants in the intervention group and 11 in the control group 
had rates of <30%.  
Event rates  are shown in table 4.    The mean (SD) days in study was 351 (117) days for the 
intervention group, and 358 (101) days for the control group. Figure 5 shows the timing of rescue 
oral steroids required during the study.   
 
 
 
 Event rate (per 100 child days) P value IRR 95% CI 
Intervention Control 
GP/ED visits (n=193)  0.582 0.650 0.316 1.15 0.83,1.63 
Days off school due to 
asthma (n=462) 
1.365 1.606 0.1 1.16 0.97,1.39 
Courses of oral steroids 
(n=156) 
0.411 0.676 0.008 1.53 1.11, 2.11 
Hospital admissions 
(n=20) 
0.0254 0.129 <0.001 4.38 1.46,12.13 
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Table 4 Incident rates for clinical outcomes. n = total number of events in study as reported by 
parents. IRR = Incident Rate Ratio. CI = Confidence Interval. Example interpretation: controls are 
53% more likely to be prescribed steroids than those in the intervention. 
There were no significant differences between the two groups for short acting β-agonist use, change 
in BTS stage, mini PAQLQ, BMQ or IPQ scores.  FEV1% improved in both treatment arms, with  no 
significant difference between treatments at 12-months compared to baseline (table 2). The mean 
(SD) beclometasone equivalent ICS dose at the end of the study was 673 (303) mcg in the 
intervention group,  and 767 (369) mcg in the control group.   
 
Clinic visits 
Patients did not attend (DNA) or cancelled 143 scheduled appointments (73 intervention, 66 
control). Appointments were re-scheduled, but where this was not possible,   35 non-clinical study 
visits (15 intervention, 20 control) were performed by the study team.. As a result of these missed 
study visits, only 41% of participants in the intervention group received feedback at all three time 
points (3,6 & 9 months). Missing data for ACQ and adherence is shown in tabulated form in 
Appendix 1.  
 
Issues with electronic adherence monitors 
Table 5 shows the frequency of devices lost, forgotten or broken.  Missed data from forgotten 
devices was downloaded at a later clinic appointment. Table 5 shows the rates of device 
malfunction, forgotten, and lost devices. Reasons given for being damaged (just reported, or actually 
broken) included lost/flat battery, dropped on floor, dropped in liquid, alarms not starting, alarms 
not stopping, screens peeled off.   
 Intervention (47 
participants) 
Control (42 participants) 
Device reported as 
“broken” by child 
23(50%) 8 (19%) 
Devices damaged beyond 
repair,  
(when inspected by study 
team, requiring 
replacement device) 
17(37%) 2 (5%) 
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Participant forgot to bring 
device to clinic 
10 (22%) 18 (43%) 
Devices lost completely 5(11%) 2 (5%) 
Table 5:  Broken, forgotten and lost devices 
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DISCUSSION 
While use of electronic adherence monitoring with feedback and regular alarms by children with 
poorly controlled asthma did not significantly improve self–reported asthma control, there was a 
significant increase in adherence rates that was maintained over the 12 months.  This improvement 
was associated with a significant decrease in the number of exacerbations requiring a course of oral 
steroids or an admission to hospital. This is the first study to our knowledge that has shown that 
regular alarms and feedback of electronic adherence data has a significant effect on a number of 
clinically important outcomes.   Importantly, the intervention was built into  routine clinical care  and 
the benefits were sustained over the  12 month study period.   
Previous studies using this approach have also demonstrated improved adherence through the use 
of reminders with or without feedback, but they have generally failed to demonstrate a significant 
difference in clinical outcomes.  These studies have variously  involved relatively well controlled and 
adherent subjects29, relatively mild asthmatic subjects managed in the community30 or have been 
too small to demonstrate significant difference19. In this study the subjects all had ‘poorly controlled 
asthma’ (ACQ ≥ 1.5)  and hence there was possibly greater potential to have an impact than those 
with apparently milder disease or pre-existing reasonable adherence.   Our results are consistent 
with the study of Williams et al., who in a study of 298 adults with asthma found that patients with 
an adherence in excess of 75%, as assessed by pharmacy records, were significantly less likely to 
require an ED  visit, courses of oral steroids or hospital admission6. 
The results from this study suggest that this approach is likely to be beneficial if introduced into 
routine clinical care, at least in those children with poor asthma control.   It is likely that the 
intervention resulted in an overall reduction in health costs, given that the majority of the direct 
costs associated with asthma are attributable to  hospital admissions, or  exacerbations sufficient to 
require intervention31.  In this study the hospitalisation rate was five times higher in the control 
group despite self-reported symptoms being similar. This approximates to the prevention of 12 
hospitalisations in one year amongst the 47 intervention subjects giving an approximate figure for 
the number to treat of 3.25.  There would appear to be a cost saving in using this approach, even at 
current prices (£120 per device). The BTS questioned the utility of this approach due to high device 
cost, but its introduction into routine practice would reduce unit price, as it would drive competition 
and innovation.   
Adherence in the control group fell progressively over the year, consistent with that reported in 
other studies 29, 30, 32.  The 49% median adherence amongst control subjects is similar to the median 
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of 53% derived from  analysis of 18 studies using electronic monitoring to record adherence rates in 
children9.  Which part of the intervention has the greatest impact is unclear since a previous study 
found reminders alone can have an impact on adherence30. However, this was in a self-selecting 
group of well controlled adult subjects whose mean adherence was high (74%) in the control group.  
It is likely that feedback contributed to the sustained improvement in adherence seen in this study 
across 12 months which contrasts with the declining adherence observed in other studies despite 
the use of reminder alarms20, 29.  Burgess et al also maintained improved adherence using feedback 
of adherence data, though the study only ran for 4 months and subjects were seen every 4 weeks19. 
The perceived advantage of having accurate electronic data was that it enabled an open and honest 
discussion about adherence and the barriers encountered, leading to evolving practical solutions. 
Social--desirability could be used in a positive way to influence medication taking behaviour. 
However, for a number the interventions did not appear to impact on adherence and there were a 
disproportionate number in this group who reported damaged or lost devices.  This approach may 
not fully address the issue of intentional non-adherence, but it does help to confirm the problem, 
should the devices remain operational. 
Both groups required less courses of oral steroids during the study than at baseline, with 
significantly fewer in the intervention group. Whilst the control group required  more rescue courses 
of oral steroids throughout, the difference between groups  was more marked at nine and twelve 
months, with rates increasing in the control group in the second six months (figure 6). Similar 
patterns of increasing control group rates  in the second six months were seen for hospital 
admissions, days off school and GP/ED visits. This would suggest the benefit of this intervention was 
over a prolonged period of time, maintaining increased adherence rates with regular feedback and 
discussion.  
In support of the argument that feedback and discussion are important are the results from a recent 
study which demonstrated that in 220 children, despite improving self-reported asthma control, 
electronic monitoring and alarms had no effect on objective clinical outcomes20.  Subjects were seen 
out of clinic every 2 months for 6 months, with adherence declining at each  time point in both 
groups, possibly leading to the initial impact on exacerbations disappearing beyond 2 months. 
Importantly the participants received no direct feedback, preventing the opportunity to initiate an 
open dialogue. Moreover, covert adherence monitoring was used, an approach that cannot be 
recommended in routine practice.   
16 
 
Out of necessity this was an open label study. The risk of introducing an inadvertent bias was 
minimised by ensuring both groups had the same number of clinic visits (136 intervention, 124 
control) and ensuring clinical management was undertaken by the patients’ usual clinicians.  The 
control participants were aware that their adherence was being monitored in a clinical trial, and the 
increased rates seen at 3 months may be due to this33. It is possible that true adherence was lower in 
the intervention group than that recorded as the devices simply record actuations with no guarantee 
the medication was inhaled. Participants or families in the intervention group may have actuated the 
device without inhalation as a way of stopping the alarms. All EMDs currently available are 
susceptible to this behaviour, by detecting canister movement rather actual inhalation. Future 
devices are likely to overcome this phenomenon by incorporating thermistors into the devices. 
These log an actuation by detecting change in air flow, generated by  inhalation, and have been used 
successfully in electronic respiratory rate monitors34.  
The lack of difference in ACQ in the two groups despite what appear to be significant differences in 
adherence rates is consistent with results reported in other studies29, 30.   Similarly recent community 
studies have reported a disconnect between self-reported symptoms and other clinical outcomes 
such as exacerbations30, 35.  This is possibly because the ACQ score is a subjective measure.  Open, 
honest dialogue facilitated by adherence discussions may have made children more honest about 
the severity of their symptoms in the intervention group. In contrast, answers from control subjects 
may have been more guarded, with denial of symptoms, as is the case in standard clinical practice, 
particularly in adolescents36. Additionally patients who knew their adherence has been poor may 
have minimised symptom reporting13. We did not record  the fraction of exhaled nitric oxide (FeNO) 
in this study, but it would have been beneficial as an alternative objective measurement of 
adherence to inhaled steroids and asthma control37.   The ACQ scores and FEV1% may also reflect 
short term influences such as the recent use of oral steroids, which was significantly more common 
in the control group. The lack of a significant difference in FEV1% between groups and poor 
correlation with exacerbations may be due to FEV1% being an inaccurate way of grading asthma 
severity in children38. 
This was designed to be a pragmatic study in which asthmatic children continued with usual care 
with or without the intervention.  There was a high rate of participants cancelling their clinic 
appointments, or simply not attending.  This appears to reflect the attitude of many patients and 
their families who don’t necessarily always consider asthma a significant condition. The overall DNA 
rate in this study was 20% (71/360 appointments, 38 group A, 33 group B), and this compares to a 
rate of 12% in respiratory clinics in Sheffield. This may demonstrate a reluctance to attend if the 
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participant felt they may be judged or blamed for poor adherence by the study team or parent. 
Alternatively, due to their improved clinical condition (shown by improved ACQ),  participants may 
have missed appointments because they felt better, a common reason for non- attendance39. 
Related to this issue were the high levels of devices reported to be ‘broken’.  Patel and colleagues 
reported a Smartinhaler malfunction rate of 1.9%, and 3.5% lost when assessing 2642 monitors 
given to adults in a clinical study12. Our rates of malfunction and loss were much higher (35% and 8% 
respectively), suggesting some of the devices were deliberately broken or lost. The higher rates in 
the intervention group (50% broken, 11% lost) suggest that children are more likely to break or lose 
their device when  their adherence is being openly monitored. The next generation of devices 
provide automated uploading of data via smartphones such that adherence can be monitored in 
real-time, which offers significant advantages in terms of logistics and opportunity to influence 
behaviour.  These high rates of damage may suggest that this approach is unpopular with the young 
people in this study. However, devices were popular, and positive feedback was received,, with the 
majority of participants asking to keep their device after the study period.  A recent qualitative study 
to investigate young people’s opinions on electronic monitoring and feedback using these 
smartinhaler devices alsoreported positive opinions, concluding  that this is a popular intervention 
for both adolescents and their parents 40.   
 In summary, these data indicate that significant clinical benefits can be derived from using 
electronic adherence monitoring with feedback and alarms. A sustained improvement in adherence 
rates was associated with a decreased number of courses of oral steroids required  and hospital 
admissions when used in a population of poorly controlled asthmatic children using combination 
therapy. 
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Figure legends 
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Figure 1 – “Smartturbo” and “Smarttrack” electronic adherence monitors. Adherium, New Zealand 
Figure 2 – Adherence review graph from http://www.smartinhalerlive.com. The number of daily 
doses taken is the y axis, with the date on the x axis.  In this example the participant was prescribed 
4 doses on the first date, but only took 2. 
Figure 3 – CONSORT 2010 flow diagram showing progress of participants through trial 
Figure 4 – Box and whisker plot showing median ACQ scores over time for groups A (intervention) 
and B (control)  
Figure 5 – Box and whisker plot showing median adherence rates over time for groups A 
(intervention) and B (control) 
Figure 6 – Bar chart demonstrating the number of courses of oral steroids required for different time 
periods during the study for groups A (intervention) and B (control). Group A total 65 courses, Group 
B total 91 courses 
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